Bone-targeted imaging and radionuclide therapy in prostate cancer

Andrei H. Iagaru, Erik Mittra, Patrick M. Colletti, Hossein Jadvar

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as 18F-NaF for the diagnosis of bony disease and 223RaCl2 for the therapy of bone metastases-were recently shown to be superior to standard 99mTc-phosphonates for diagnosis and 153Sm-ethylenediaminetetramethylene phosphonate or 89SrCl2 for therapy. The advantages of 18F-NaF include improved lesion detection and, when used in combination with CT, improved diagnostic confidence and specificity. In addition to being the first approved α-emitter, 223RaCl2 is the first radiopharmaceutical to show an increase in overall survival, a decrease in skeletal events, palliation of bone pain, and a low profile of adverse reactions (which are mild and manageable). The management of metastatic bone disease with 223RaCl2 is uniquely satisfying, as patients can be monitored directly during their monthly treatment visits.

Original languageEnglish (US)
Pages (from-to)19S-24S
JournalJournal of Nuclear Medicine
StatePublished - Oct 1 2016
Externally publishedYes


  • Bone
  • Cancer
  • PET
  • PET/CT
  • Prostate
  • Radium

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Bone-targeted imaging and radionuclide therapy in prostate cancer'. Together they form a unique fingerprint.

Cite this